Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blood Cancer Sector More Competitive After Keytruda Approval

Executive Summary

The US FDA approval of Keytruda in its first hematologic cancer indication will put Merck & Co in a position to compete with Bristol-Myers Squibb, whose own checkpoint inhibitor Opdivo gained a similar, but not identical, marketing approval in classical Hodgkin lymphoma last year.

Advertisement

Related Content

CHMP Opinions: Opdivo Sees Keytruda's Hodgkin's And Raises It Head & Neck
Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098400

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel